ImmunoGen, Inc. (IMGN) News
Filter IMGN News Items
IMGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMGN News Highlights
- IMGN's 30 day story count now stands at 5.
- Over the past 22 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about IMGN are ADD, DRUG and HUGE.
Latest IMGN News From Around the Web
Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., September 29, 2023--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerWALTHAM, Mass., September 28, 2023--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC). The findings will be |
These 7 Stocks Are Outperforming Nvidia In 2023Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 996%, leading seven huge winners this year. |
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerWALTHAM, Mass., September 18, 2023--ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer |
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue GrowthPharma stocks can be a great investment, particularly if they have solid performance, revenue growth and a positive outlook. |
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in JapanWALTHAM, Mass., August 28, 2023--ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan |
5 Meme Stocks to Sell Immediately, According to AIAs we move into September, the MarketMaster AI is flashing warning signals about risky equities. |
These Are the ONLY 3 Biotech Stocks to Consider in August 2023These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. |
7 A-Rated Biotech Stocks for Your August Buy ListInvesting in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. |
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales BeatImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023. |